Aldeyra Therapeutics
Market cap $41.9M 60.4M shares (10-Q, Nov 3, 2026) × $0.694 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- ADX-246 IND filing2026ADX-246 IND filing, 2026, notable
- ADX-248 Ph2 start2H 2026ADX-248 Ph2 start, 2H 2026, routine
- FDRR appeal corporate update4Q 2026FDRR appeal corporate update, 4Q 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
reproxalap
methotrexate
ADX-2191ADX-248
ADX-246
Technology platforms
RASP Modulator Platform
Platform of small molecule reactive aldehyde species (RASP) modulators that covalently bind and deplete RASP, modulating multiple inflammatory protein systems simultaneously. Disease focus includes ocular inflammatory diseases (dry eye disease, allergic conjunctivitis, age-related macular degeneration), systemic immune-mediated diseases (atopic dermatitis, psoriasis, asthma), and rare retinal diseases.
Targets: RASP, reactive aldehyde species
RASP Platform for Immune-Mediated Diseases
Reactive aldehyde species (RASP) modulation platform targeting immune-mediated diseases; disease focus includes dry eye disease, allergic conjunctivitis, atopic dermatitis, Sjögren-Larsson syndrome, obesity/hypertriglyceridemia, moderate alcohol-associated hepatitis, and CNS/neuroinflammatory disease.
Platform for Rare Retinal Inflammatory Diseases
Platform focused on rare retinal inflammatory diseases; lead candidate ADX-2191 administered via intravitreal injection for primary vitreoretinal lymphoma and proliferative vitreoretinopathy.
Discontinued (3)
- methotrexate — Retinitis Pigmentosa · suspension of the ADX-2191 retinitis pigmentosa clinical development program
- ADX-629 — undisclosed · completed proof-of-concept testing; no longer in development aside from potential investigator-sponsored trials in Sjögren-Larsson Syndrome
- ADX-2191 — Proliferative Vitreoretinopathy · Company ceased development of the Helio Product Candidate for the treatment of proliferative vitreoretinopathy during year ended December 31, 2024
Capital (as filed)
- Cash
- $41.0M cash, equivalents and restricted cash · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$4.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $41.0M cash, runway into 2029 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (10)
- 2026-11-10 UPDATE: Aldeyra Therapeutics (ALDX) - Tearing Up the Blueprint 🔒 Paid
- 2026-11-06 UPDATE: Aldeyra Therapeutics (ALDX) - Trading at Cash, Knocking on Nasdaq’s Door 🔒 Paid
- 2026-09-30 UPDATE: Aldeyra Therapeutics (ALDX) - Going Over the Division’s Head 🔒 Paid
- 2026-08-07 UPDATE: Aldeyra Therapeutics (ALDX) - The Floor Keeps Sinking 🔒 Paid
- 2026-07-15 UPDATE: Aldeyra Therapeutics (ALDX) - The FDA Punts, Aldeyra Escalates
- 2026-05-08 UPDATE: Aldeyra Therapeutics (ALDX) - The Cash Floor Just Got Lower 🔒 Paid
- 2026-05-02 UPDATE: Aldeyra Therapeutics (ALDX) - Reading the FDA’s Margin Notes 🔒 Paid
- 2026-03-21 UPDATE: Aldeyra Therapeutics (ALDX) - The Bottom Falls Out 🔒 Paid
- 2026-02-28 UPDATE: Aldeyra Therapeutics (ALDX) - The Final Countdown to PDUFA 🔒 Paid
- 2025-12-17 BONUS: Aldeyra Therapeutics (ALDX): Scientific Due Diligence for Reproxalap and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (10 calls)
Every verdict Biotech Distilled has published on Aldeyra Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2025-12-17 Watch BONUS: Aldeyra Therapeutics (ALDX): Scientific Due Diligence for Reproxalap and Pipeline Products Binary PDUFA event on March 16, 2026; science is theoretically sound but clinical data is mixed and regulatory path is a minefield — wait for the FDA decision before taking a position.
- 2026-02-28 Watch UPDATE: Aldeyra Therapeutics (ALDX) - The Final Countdown to PDUFA Runway is secure into the PDUFA, AbbVie option mechanics confirmed on a 10-day fuse post-approval, but the binary risk from mixed field/chamber data remains — maintain Watch List into the March 16 decision.
- 2026-03-21 Watch UPDATE: Aldeyra Therapeutics (ALDX) - The Bottom Falls Out CRL issued with no new trials demanded and insider buying on the dip; AbbVie deal is off the table for now but the RASP platform retains optionality as a deep-value special situation — no explicit change from Watch List.
- 2026-05-02 Watch UPDATE: Aldeyra Therapeutics (ALDX) - Reading the FDA's Margin Notes Trial-by-trial FDA scorecard published; allergic conjunctivitis optionality undervalued; cash floor real with runway into 2028 — maintain Watch List pending Q2 Type A meeting outcome.
- 2026-05-08 Watch UPDATE: Aldeyra Therapeutics (ALDX) - The Cash Floor Just Got Lower Hercules debt payoff reduces effective cash to ~$50M and a securities class action adds legal overhang, but AbbVie option remains live and Type A meeting is still the near-term catalyst — Watch List maintained.
- 2026-07-15 Watch UPDATE: Aldeyra Therapeutics (ALDX) - The FDA Punts, Aldeyra Escalates Type A minutes were ambiguous, Aldeyra requested clarification and escalated to a Type D meeting by end of Q3 — timeline extended by a quarter but bounded-downside thesis intact; Watch List maintained.
- 2026-08-07 Watch UPDATE: Aldeyra Therapeutics (ALDX) - The Floor Keeps Sinking Cash fell to $45.1M, new FDRR risk-factor language signals FDA dialogue is not converging, pipeline initiations are unfunded and overdue — but AbbVie option still live and Type D meeting still the catalyst; Watch List maintained.
- 2026-09-30 Avoid UPDATE: Aldeyra Therapeutics (ALDX) - Going Over the Division's Head Type D meeting failed to persuade the review division; Aldeyra filing a Formal Dispute Resolution Request — the bearish tell the author flagged in August has now fired, downgrading to AVOID until the OND decision.
- 2026-11-06 Avoid UPDATE: Aldeyra Therapeutics (ALDX) - Trading at Cash, Knocking on Nasdaq's Door Stock has fallen to roughly net cash per share (~$0.64), Nasdaq bid-price deficiency clock is ticking, FDRR filed with historically minority success rate, and none of the September triggers for returning to Watch List have fired — AVOID maintained.
- 2026-11-10 Avoid UPDATE: Aldeyra Therapeutics (ALDX) - Tearing Up the Blueprint Aldeyra withdrew the agreed ADX-2191 PVRL SPA and requested a division transfer, eliminating the last dated pipeline program, warning of higher costs and possible earlier dilution, and flagging risk to the reproxalap FDRR — AVOID maintained.
- Avoid call · opened Sep 30, 2026 at $1.23 · -43.6% vs XBI -7.9% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (19)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 20268-KCurrent report: listing notice
- Nov 9, 20268-KCurrent report: other events→ BD updateAldeyra just blew up the last piece of regulatory certainty in its pipeline — withdrawing the FDA-agreed trial design for ADX-2191 in PVRL and asking for the entire program to be reassigned to a different review division, with no guarantee it will be accepted.
- Nov 5, 202610-QQuarterly report→ BD update
- Sep 29, 2026ReleaseAldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease→ BD updateSummary on the 8-K
- Sep 29, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateAfter a September 25 Type D meeting that failed to converge with the FDA review division, Aldeyra is escalating to a Formal Dispute Resolution Request — appealing the March CRL to the Office of New Drugs itself — while extending cash runway to 2029 and publishing the most detailed public data defense of reproxalap yet.BD extracted 1 program update from this document → ALDX pipeline
- Sep 28, 2026ReleaseAldeyra Therapeutics to Host Regulatory Update Webcast
- Aug 6, 202610-QQuarterly report
- Jul 30, 20268-KCurrent report: material agreement
- Jul 15, 20268-KCurrent report: other events
- Jun 10, 20268-KCurrent report: officer / director change, shareholder vote, Reg FD disclosure · EX-99.1
- Jun 9, 2026ReleaseAldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
- Jun 2, 2026ReleaseAldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- May 7, 202610-QQuarterly report
- May 1, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Apr 27, 2026DEFA14AProxy soliciting material
- Apr 27, 2026DEF 14AProxy statement
- Apr 20, 20268-KCurrent report: officer / director change
- Apr 1, 20268-KCurrent report: other events
- Mar 17, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 12, 2026SCHEDULE 13G/A13G amendment
- Nov 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 12, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 27, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 27, 2026ARSAnnual report to shareholders
- Mar 26, 2026SCHEDULE 13G/A13G amendment